Treatment of Cutaneous Lupus Erythematosus (CLE) With the 595 nm Flashlamp Pulsed Dye Laser

Completed · Phase 2

Conditions studied: Cutaneous Lupus Erythematosus

In brief

The purpose of using the 595 nm Vbeam Perfecta™ flashlamp-excited, pulsed dye laser in this study is to help improve study patients' skin disease. Cutaneous lupus erythematosus (CLE) often presents with disfiguring vascular lesions which are frequently difficult to treat with the available therapeutic measures, such as photoprotection, topical steroids, and antimalarials. Laser therapy provides an alternative treatment option for CLE patients. Although there has been documented experience with laser treatment in CLE patients, no study comparing treated lesions to the natural course of the disease has been conducted.

Key facts

Study ID

NCT00523588

Run by

University of Pennsylvania

People needed

10

Starts

2007-03-01

Expected to finish

2010-01-01

Last updated by the study team

2010-06-25

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Cutaneous lupus erythematosus confirmed by histological analysis
• Fitzpatrick I-III skin type (very fair, fair, or medium skin)
• Stable disease and in relatively good health
• Presence of two skin lesions that are suitable for laser treatment
• Written informed consent available prior to any screening procedures
• Female patients must be willing to use the appropriate birth control measures that will prevent pregnancy from the time of signing informed consent through 60 days after their last laser treatment

You may not qualify if…

• Clinically significant dyspigmentation
• History of isotretinoin use, phenol peels, filler injections (collagen, fat), dermabrasion within the past 3 years
• History of hypertrophic scarring
• History of photosensitivity in the 585-600 nm wavelength region
• History of seizure disorders triggered by light
• Pregnancy and lactation
• Fitzpatrick V or VI skin type (moderately pigmented brown, or markedly pigmented black skin)
• Patients receiving anticoagulants and/or medication for which sunlight exposure is a contraindication
• Known malignancy or prior malignancy, other than non-melanoma skin cancer

Where it is running

• University of Pennsylvania, Department of Dermatology — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.